Management of Fatigue in Patients with Advanced Cancer
- PMID: 36656503
- PMCID: PMC9883329
- DOI: 10.1007/s11864-022-01045-0
Management of Fatigue in Patients with Advanced Cancer
Abstract
Fatigue is a common and distressing symptom experienced by patients with cancer. It is most common in patients with locally advanced or metastatic incurable disease. It can have profound effects on quality-of-life and physical functioning. In addition to general supportive measures (directed at tackling contributory conditions and comorbidities), a variety of specific interventions have been developed which can be broadly categorised as physical therapies, psychological therapies or medication. There is some evidence that each of these approaches can have benefits in patients with earlier stage disease, those undergoing active treatment and in cancer survivors. The best evidence is for aerobic exercise, yoga, cognitive-behavioural therapy (CBT) and psycho-educational interventions. Less strong evidence supports the use of medications such as methylphenidate or ginseng. In patients with advanced disease, it is likely that the mechanisms of fatigue or the factors contributing to fatigue maintenance may be different. Relatively fewer studies have been undertaken in this group and the evidence is correspondingly weaker. The authors recommend the cautious use of aerobic exercise (e.g. walking) in those who are still mobile. The authors advise considering the use of psycho-educational approaches or CBT in those patients who are able to engage in such forms of therapy. In patients near the end-of-life, the authors advise use of dexamethasone (short-term use) and other pharmacological treatments only on the basis of a clinical trial.
Keywords: Exercise; Fatigue; Neoplasm; Palliative care; Psychotherapy; Therapeutics.
© 2022. The Author(s).
Conflict of interest statement
Prof Stone reports that he is the Chief Investigator of an on-going randomised controlled trial of methylphenidate versus placebo for fatigue in advanced cancer funded by the UK National Institute for Health Research Health Technology Assessment programme. Dr Candelmi has nothing to disclose. Dr Kandola has nothing to disclose. Dr Montero has nothing to disclose. Dr Smeetham has nothing to disclose. Dr Suleman has nothing to disclose. Dr Fernando has nothing to disclose. Dr Roji has nothing to disclose.
References
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- Jankowski C, Berger A, Aranha O, Banerjee C, Breitbart W, Carpenter K, et al. NCCN Guidelines Version 2.2022 Cancer-Related Fatigue. NCCN. 2022;https://www.nccn.org/. Evidence-based guidelines that are updated regularly and relate to patients on and off treatment and in patients at the end-of-life.
-
- Soones T, Ombres R, Escalante C. An update on cancer-related fatigue in older adults: a narrative review. J Geriatr Oncol. 2022;13(2):125–131. - PubMed
-
- Chapman EJ, Martino ED, Edwards Z, Black K, Maddocks M, Bennett MI. Practice review: evidence-based and effective management of fatigue in patients with advanced cancer. Palliat Med. 2022;36(1):7–14 Pragmatic guideline that gives short and general recommendations for the management of fatigue in patients with advanced cancer. - PMC - PubMed
-
- Maqbali MA. Cancer-related fatigue: an overview. British Journal of Nursing. 2021;30(4):S36–S43. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
